Necrostatin 2 racemate (Synonyms: 7-Cl-O-Nec-1, Nec-1s) |
|
カタログ番号GC36711
|
Necrostatin 2 racemateは高い特異性を持つ受容体相互作用のタンパク質キナーゼ1(RIPK1)阻害剤であり、インドールアミン2,3-ジオキシゲナーゼ(IDO)の活性を影響しない。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 852391-15-2
Sample solution is provided at 25 µL, 10mM.
Necrostatin 2 racemateは高い特異性を持つ受容体相互作用のタンパク質キナーゼ1(RIPK1)阻害剤であり、インドールアミン2,3-ジオキシゲナーゼ(IDO)の活性を影響しない[1]。Necrostatin 2 racemateはよく、炎症疾患(例えば関節リウマチ)、神経変性疾患(例えばアルツハイマー病やパーキンソン病など)と臓器保護の研究に使われている[2, 3]。
体外で、Necrostatin 2 racemate (1μM)でpro-B exosomes+リンパ球を48時間処理した結果、cytosporone B (10μM)誘発のアポトーシスを著しく増強し、平均アポトーシス率は63.14%で、対照群(10%)よりも約628%高かった[4]。Necrostatin 2 racemate (45μM)で野生型骨髄由来のマクロファージ(BMDM)を事前処理し、続いてヘムとPam3CSK4 (Pam3)で48時間共同処理した結果、ヘムとPam3誘発の細胞死亡を部分的に阻害した;この保護作用は、z-VAD-FMK (zVAD)との併用で更に増強された[5]。A549とH358細胞をNecrostatin 2 racemate (10μM)と銅ベースの金属有機構造体(Cu-MOF)で72時間共同処理した結果、Cu-MOF誘発の細胞毒性を逆転させ、細胞の生存率を部分的に回復させた[6]。
体内で、アンジオテンシンII (Ang II)の潅流から始め、28日間、Necrostatin 2 racemate (1.6mg/kg/day)をアポリポタンパク質E欠乏症(ApoE-/-)のマウスに毎日腹腔内投与した結果、腹部大動脈瘤(AAA)の形成を著しく軽減し、AAAの発生率を減らした[7]。壊死性腸炎(NEC)の新生マウスモデルに、Necrostatin 2 racemate (2mg/kg/day;毎日一回)を、NECの誘発から始め、3日間毎日腹腔内注射した結果、生存率を著しく改善し、腸の組織病理学的損傷を軽減し、炎症促進のサイトカイン(IL-1β、IL-17、TNF-αとIFN-γ)の発見を減らした[8]。
References:
[1] YU J, ZHONG B, ZHAO L, et al. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors Necrostatin-1 (Nec-1) and 7-Cl-O-Nec-1 (Nec-1s) are potent inhibitors of NAD(P)H: Quinone oxidoreductase 1 (NQO1)[J]. Free Radical Biology and Medicine, 2021, 173: 64-69.
[2] YU Z, JIANG N, SU W, et al. Necroptosis: a novel pathway in neuroinflammation[J]. Frontiers in Pharmacology, 2021, 12: 701564.
[3] MIFFLIN L, OFENGEIM D, YUAN J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target[J]. Nature Reviews Drug Discovery, 2020, 19(8): 553-571.
[4] GENTIMIR C A, GELEŢU G, CHELARU L, et al. Biochemical effects of TLRs, CXCL12, and necrosome activation on pro-B lymphocyte apoptosis in the presence of fibroblasts[J]. Romanian Journal of Oral Rehabilitation, 2022, 14(3).
[5] SUNDARAM B, PANDIAN N, MALL R, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs[J]. Cell, 2023, 186(13): 2783-2801.
[6] LI K, WU L, WANG H, et al. Apoptosis and cuproptosis co-activated copper-based metal-organic frameworks for cancer therapy[J]. Journal of Nanobiotechnology, 2024, 22(1): 546.
[7] WANG Q, ZHOU T, LIU Z, et al. Inhibition of Receptor-Interacting Protein Kinase 1 with Necrostatin-1s ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model[J]. Scientific Reports, 2017, 7(1): 42159.
[8] LIU T, ZONG H, CHEN X, et al. Toll-like receptor 4-mediated necroptosis in the development of necrotizing enterocolitis[J]. Pediatric Research, 2022, 91(1): 73-82.
| 細胞実験[1]: | |
細胞株 | BMDM(骨髄由来のマクロファージ) |
準備方法 | BMDMを45μM Necrostatin 2 racemate (zVADがある/ない)、ヘムとPam3の併用で48時間処理し、細胞死亡の動態を、IncuCyte S3またはSX5生細胞分析システムで監視した。 |
反応条件 | 45μM;48時間 |
アプリケーション | Necrostatin 2 racemateの処理は、PBSの対照と比べ、ヘムとPam3に反応した細胞死が部分的に減り、zVADの追加で細胞死がさらに減った。 |
| 動物実験 [2]: | |
動物モデル | ApoE-/- マウス(アポリポタンパク質E欠損マウス) |
準備方法 | ApoE-/-マウスに、1000ng/kg/分の速度でアンギオテンシンIIを分泌する浸透圧ポンプを移植した。その直後に、Necrostatin 2 racemate(1.6mg/kg/日;腹腔内投与)を毎日投与し始めた。28日後、マウスを安楽死させた。大動脈外径を、デジタルノギスを使い、最大の拡張を示す部位で測定した。動脈瘤の発生率を、腎下部領域の外幅と比べて腎上部大動脈の外幅が50%以上増加したことと定義した。 |
投与形態 | 1.6mg/kg/day;28日間;腹腔内注射 |
アプリケーション | DMSO群と比べて、Necrostatin 2 racemateで処理されたマウスで、動脈瘤の形成が著しく改善され、大動脈拡張が著しく減り(Nec-1s: 55.40 ± 13.08% vs. DMSO: 121.1 ± 16.44%, P < 0.05)、AAA発生率も減った(90.5%から33.3%に)。 |
References: | |
| Cas No. | 852391-15-2 | SDF | |
| 同義語 | 7-Cl-O-Nec-1, Nec-1s | ||
| Canonical SMILES | ClC1=C2C(C(CC3C(N(C)C(N3)=O)=O)=CN2)=CC=C1 | ||
| Formula | C13H12ClN3O2 | M.Wt | 277.71 |
| 溶解度 | DMSO: ≥ 50 mg/mL (180.04 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6009 mL | 18.0044 mL | 36.0088 mL |
| 5 mM | 720.2 μL | 3.6009 mL | 7.2018 mL |
| 10 mM | 360.1 μL | 1.8004 mL | 3.6009 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)